Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1998-12-04
2008-08-12
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007240, C530S388220, C530S388730, C530S389600
Reexamination Certificate
active
07410767
ABSTRACT:
The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.
REFERENCES:
patent: 3112485 (1991-05-01), None
patent: 3112486 (1991-05-01), None
patent: 3112487 (1991-05-01), None
Braud et al. Nature, 391:795-799, 1998.
Aldrich et al (1994) Cell 79:649-658.
Brooks et al. Journal of Immunology (1999) 162:305-313.
Mingari, MC et al. Int. Immunol. [1995] 7(4):697-703.
Borrego, Francisco et al.: “Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence-derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell-mediated Lysis” Journal of Experimental Medicine, (Mar. 2, 1998), vol. 187, No. 5, pp. 813-818.
Braud, Veronique M. et al.: “HLA-E Binds to Natural Killer Cell Receptors CD94/NKG2A, B and C” Nature London), (Feb. 19, 1998), vol. 391, No. 6669, pp. 795-799.
O'Callaghan, Christopher et al.: “Structural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E” Molecular Cell, (Mar. 1998), vol. 1, No. 4, pp. 531-541.
Leibson, Paul J.: “Cytotoxic Lymphocyte Recognition of HLA-E: Utilizing a Nonclassical Window to Peer into Classical MHC” Immunity, (Sep. 1998), vol. 9, No. 3, pp. 289-294.
Posch et al.: “HLA-E is the Ligand for the Natural Killer Cell CD94/NKG2 Receptors” Journal of Biomedical Science, (Sep. 1998), vol. 5, No. 5, pp. 321-331.
Llano, M. et al.: “HLA-E Bound Peptides Influence Recognition by Inhibitory and Triggering CD94/NKG2 Receptors: Preferential Response to an HLA-G-Derived Nonamer” Eur. J. Immunol. (Sep. 1998), vol. 28, No. 9, pp. 2854-2863.
O'Callaghan, Christopher et al.: “Structure and Function of the Human MHC Class Ib Molecules HLA-E, HLA-F and HLA-G” Immunol. Rev., (1998), vol. 163, pp. 129-138.
Aramburu et al., “A Novel Functional Cell Surface Dimer (Kp43) Expressed By Natural Killer Cells And T Cell Receptor γ/δ+Lymphocytes,” The Journal of Immunology, vol. 144, No. 8, pp. 3238-3247 (1990).
Houchins et al., “DNA Sequence Analysis of NKG2, a Family of Related cDNA Clones Encloding Type II Integral Membrane Proteins on Human Natural Killer Cells,” J. Exp. Med., vol. 173, pp. 1017-1020 (Apr. 1991).
Ulbrecht et al., “The HLA-E Gene Encodes Two Differently Regulated Transcripts And A Cell Surface Protein,” The Journal Of Immunology, vol. 149, No. 9, pp. 2945-2953 (1992).
Ulbrecht et. al., “Impaired Intracellular Transport and Cell Surface Expression of Nonpolymorphic HLA-E: Evidence for Inefficient Peptide Building,” J Exp Med, vol. 176, pp. 1083-1090 (1992).
Shawar et al., “Antigen Presentation By Major Histocompatibility Complex Class I-B Molecules,” Annual Review of Immunology, vol. 12, pp. 839-880 (1994).
Pérez-Villar, et al, “Functional Ambivalence of the Kp43 (CD 94) NK Cell-Associated Surface Antigen,” The Journal of Immunology, vol. 154, pp. 5779-5788 (1995).
Phillips et al., “CD94 and a Novel Associated Protein (94AP) Form a NK Cell Receptor Involved in the Recognition of HLA-A, HLA-B, and HLA-C Allotypes,” Immunity, vol. 5, pp. 163-172 (1996).
Lazetic et al., “Human Natural Killer Cell Receptors Involved in MHC Class I Recognition Are Disulfide-Linked Heterodimers of CD94 and NKG2 Subunits,” The Journal of Immunology, vol. 157, pp. 4741-4745 (1996).
Sivori et al., “CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies,” Eur. J. Immunol., vol. 26, pp. 2487-2492 (1996).
Sivori et al., “Inhibitory CD94 Molecules Identified by the Z199 Monoclonal Antibody Recognize Different HLA-Class I Molecules,” Transplantation Proceedings, vol. 28, No. 6, pp. 3199-3203 (1996).
Carretero et al., “The CD94 and NKG-2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA clss I molecules,” Eur. Journal of Immunology, vol. 27, pp. 563-567 (1997).
Houchins et al., “Natural Killer Cell Cytolytic Activity Is Inhibited by NKG2-A and Activated by NKG2-C,” The Journal of Immunology, vol. 158, pp. 3603-3609 (1997).
Braud et al., “The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at position 2 and 9,” Eur. J. Immunol., vol. 27, pp. 1164-1169 (1997).
Plougastel et al., “Cloning ofNKG2-F, a new member of theNKG2family of human natural killer cell receptor genes,” Eur. J. Immunol., vol. 27, pp. 2835-2839 (1997).
Lanier et al., “Arousal and inhibition of human NK cells,” Immunological Reviews, Vo. 155, pp. 145-154 (1997).
Braud et al., “TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide,” Current Biology, vol. 8, No. 1, pp. 1-10 (1998).
Braud et al., “HLA-E binds to natural killer cell receptors CD 94/NKG2A, B and C,” Nature, vol. 391, pp. 795-799 (1998).
Lee et al., “HLA-E Surface Expression Depends on Binding of TAP-Dependent Peptides Derived from Certain HLA Class I Signal Sequences,” The Journal of Immunology, vol. 160, pp. 4951-4960 (1998).
Lanier et al., “Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells,” Nature, vol. 391, pp. 703-707 (1998).
Allan David S. J.
Braud Veronique M.
McMichael Andrew J.
O'Callaghan Christopher A.
Ogg Graham S.
Isis Innovation Limited
Saunders David A.
VanderVegt F. Pierre
Volpe and Koenig P.C.
LandOfFree
HLA-E binding does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HLA-E binding, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-E binding will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015668